Kevin B Kim - MD Anderson Cancer Center, The University of Texas

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 123 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase II Study of Niraparib in Patients with Advanced Melanoma with Homologous Recombination Pathway Gene Mutations

Kevin B Kim,Pierre-Yves Desprez,David de Semir, Rinette W L Woo, Anima Sharma, Robyn Jones, Chongshan Caressi,Mehdi Nosrati, Emilia Janiczek, Julia Rivera Penafiel, Mohammed Kashani-Sabet

JCO precision oncology (2025): e2400658-e2400658

Cited0Views0WOSBibtex

ARID2 Mutations May Relay a Distinct Subset of Cutaneous Melanoma Patients with Different Outcomes

Favour A. Akinjiyan,George Nassief,Jordan Phillipps,Tolulope Adeyelu,Andrew Elliott,Farah Abdulla,Alice Y. Zhou,George Souroullas,Kevin B. Kim,Ari Vanderwalde,Soo J. Park,George Ansstas

Scientific Reports（2024）

Cited3Views0WOSNATUREBibtex

Preoperative and Intraoperative Identification of Sentinel Lymph Nodes in Melanoma Surgery

Stanley P. Leong,Mehdi Nosrati,Max C. Wu,Donald M. Torre, Ted F. Bartley,Kevin B. Kim, Christopher Soon,John Moretto,Mohammed Kashani-Sabet

Cancersno. 15 (2024): 2767-2767

Cited0Views0WOSBibtex

Supplementary Table, Materials and References from Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular, and Clinical Correlates

Scott E. Woodman,Jonathan C. Trent,Katherine Stemke-Hale,Alexander J. Lazar,Sabrina Pricl,Giovanni M. Pavan,Maurizio Fermeglia,Y.N. Vashisht Gopal,Dan Yang,Donald A. Podoloff,Doina Ivan,Kevin B. Kim,Nicholas Papadopoulos,Patrick Hwu,Gordon B. Mills,Michael A. Davies

openalex（2023）

Cited0Views0Bibtex

Supplementary Table 1 from Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim,Jason Chesney,Douglas Robinson,Humphrey Gardner,Michael M. Shi,John M. Kirkwood

openalex（2023）

Cited0Views0Bibtex

Supplementary Table from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i>-mutant Melanoma

Martin Schuler,Lisa Zimmer,Kevin B. Kim,Jeffrey A. Sosman,Paolo A. Ascierto,Michael A. Postow,Filip Y.F.L. De Vos,Carla M.L. van Herpen,Matteo S. Carlino,Douglas B. Johnson,Carola Berking,Micaela B. Reddy,Allison S. Harney,Jordan D. Berlin,Rodabe N. Amaria

crossref（2023）

Cited0Views0Bibtex

A Phase 1 Study of Fianlimab (Anti-Lag-3) in Combination with Cemiplimab (Anti-Pd-1) in Patients with Advanced Melanoma: Poor-prognosis Subgroup Analysis

Inderjit Mehmi,Karl D. Lewis,Amy M. Weise,Meredith McKean,Kyriakos P. Papadopoulos,John Crown,Sajeve Samuel Thomas,Eugenia Girda,John M. Kaczmar,Kevin B. Kim,Nehal J. Lakhani,Melinda Lynne Yushak,Omid Hamid,Jayakumar Mani, Fang,Israel Lowy,Giuseppe Gullo

JOURNAL OF CLINICAL ONCOLOGY（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn